絞り込み

16641

広告

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

Miscellaneous

Immune therapy with the PD1 inhibitor pembrolizumab has been approved to treat unresectable/metastatic solid tumours exhibiting mismatch repair (MMR) deficiency. Lynch syndrome (LS), caused by autosomal dominant germline mutations of a MMR gene, predisposes to the development of MMR-deficient cancers. We report a case of -LS with an MMR-intact pancreatic ductal adenocarcinoma (PDAC) ineligible for treatment with pembrolizumab.
PMID: 31275582 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード